Capricor is in the spotlight as investors await Phase 3 DMD trial data next week. The upcoming presentation at the Muscular Dystrophy conference will highlight muscle and cardiac benefits. The ongoing FDA review and pending PDUFA decision add to the buzz. CEO Linda Marban emphasised the growing clinical evidence supporting Deramiocel.